Peptide Precursors and Processing: From Propeptide to Bioactive Molecule

Reading a peptide gene sequence does not tell you what molecule the cell actually secretes. A widespread assumption in molecular biology is that a translated open reading frame directly predicts the structure of the active signaling agent. For peptide hormones, neuropeptides, and paracrine factors, that assumption is flatly incorrect. The primary translational product is almost never the functional entity that encounters a physiological receptor.

Instead, the encoded sequence functions as a precursor blueprint. It contains routing tags, multiple potential peptide cassettes, protective spacer segments, and enzymatic processing signals. To yield a functional signaling molecule, the host cell must direct this larger polypeptide through a multi-compartment assembly line. Proteolytic scissors cut internal bonds, exopeptidases trim remaining residues, and specialized enzymes remodel terminal chemistry.

Investigating precursor processing requires moving beyond sequence alignment. One must examine how intracellular trafficking, localized protease expression, and chemical modifications dictate peptide identity. Without this context, researchers risk measuring non-functional intermediates, misattributing receptor affinity, or assuming synthetic fragments mirror endogenous biology. Understanding the journey from prepropeptide to mature product reveals how biological systems generate complex molecular diversity from compact genetic instructions.

Reframe the Genetic Code as a Precursor Blueprint

A peptide gene sequence serves as an architectural template rather than an inventory of secreted agents. When a ribosome finishes translating an mRNA transcript for a peptide factor, it produces a precursor protein. This initial precursor contains far more information than the final receptor ligand. It holds topological instructions for intracellular transit, structural scaffolds that prevent premature aggregation, and the raw chemical inputs for downstream enzymatic reactions.

Confusing the genomic sequence with the mature peptide leads to serious analytical errors. A sequence database will accurately show where an open reading frame begins and ends. However, it cannot reveal which peptide bonds a specific cell type will hydrolyze. It also cannot predict whether the resulting termini will retain basic residues or undergo covalent alteration. The final molecular species depends entirely on the processing machinery of the host cell.

Scientific literature often conflates several distinct terms across this maturation pipeline. Establishing clear biochemical definitions prevents confusion:

• Prepropeptide (Precursor Protein): The primary translated polypeptide chain. It contains the N-terminal hydrophobic signal peptide alongside the sequences destined to become one or more mature peptides.
• Propeptide (Prohormone): The precursor remaining after the removal of the signal peptide. It represents an inactive or partially active intermediate that requires further proteolysis before it can engage target receptors.
• Intermediate Peptide: A partially processed proteolytic fragment. It has undergone primary endoproteolytic cleavage but retains terminal basic amino acids or lacks critical post-translational additions.
• Mature Peptide: The fully processed molecular entity. All necessary internal cleavages, terminal trimming steps, and post-translational modifications have concluded.
• Bioactive Peptide: A mature peptide that elicits a verifiable biological response at physiological concentrations. Not every peptide released from a precursor exhibits signaling activity; some segments merely act as spacers or processing chaperones.

Recognizing these distinctions changes how researchers evaluate published findings. For foundational concepts in this discipline, consult the curated materials in peptide fundamentals and biology. An encoded region in a genome is an invitation for processing, not a guarantee of a specific signaling outcome. The active signaling molecule is an emergent property of both the genetic code and the enzymatic environment of the synthesizing tissue.

Map the Molecular Architecture of Prepropeptides

Prepropeptides follow a modular design that facilitates regulated movement and sequential processing. At the extreme N-terminus sits the signal peptide, which typically spans 15 to 30 amino acids. This hydrophobic stretch forms an alpha-helix that directs the nascent polypeptide chain into the lumen of the endoplasmic reticulum. Once the peptide crosses this membrane boundary, signal peptidase cleaves the signal peptide away. This primary cleavage event converts the prepropeptide into a propeptide.

Beyond the signal sequence, the propeptide architecture organizes into distinct structural zones. Some propeptides are monovalent, containing only a single bioactive sequence surrounded by regulatory regions. Others are polyvalent cassettes that house multiple copies of the same peptide or several distinct signaling molecules arranged in tandem. These functional zones remain separated by spacer peptides that keep individual signaling domains insulated from premature folding interactions.

Crucially, propeptides embed specific cleavage signals that guide endoproteases to the correct peptide bonds. The most common processing signals consist of paired basic amino acid residues. Combinations such as lysine-arginine or arginine-arginine frequently border the bioactive domains. Monobasic sites containing a single arginine residue also operate within select precursors. These basic motifs serve as physical docking surfaces for specialized processing enzymes that execute internal cuts.

The precursor architecture also supplies chemical donor residues needed for downstream structural changes. A classic example is glycine, which frequently appears immediately adjacent to a basic cleavage site. The cell does not retain this glycine as a terminal amino acid in the final signaling ligand. Instead, the glycine serves as a sacrificial nitrogen donor for enzymatic C-terminal amidation. Understanding this structural map ensures that investigators do not mistake processing aids for active elements of the final molecule.

Trace Cellular Compartmental Routing Through the Secretory Pathway

Peptide processing does not occur in a homogenous cytoplasmic mixture. It takes place within membrane-bound organelles that maintain distinct biochemical conditions. After signal peptidase removes the signal peptide in the rough endoplasmic reticulum, the propeptide undergoes initial folding. Chaperone proteins assist in establishing the correct tertiary architecture. Disulfide bonds frequently form in this neutral-pH oxidizing environment, locking the propeptide into a stable conformation.

From the endoplasmic reticulum, transport vesicles ferry the propeptide to the cis-Golgi network. The molecule advances through the medial and trans-Golgi stacks via vesicular trafficking. Within these Golgi cisternae, early post-translational modifications can begin. Certain propeptides receive complex N-linked or O-linked glycans, while others undergo tyrosine sulfation. Throughout this migration, the luminal pH steadily declines from approximately 7.2 in the endoplasmic reticulum to around 6.0 in the trans-Golgi network.

At the trans-Golgi network, the secretory pathway diverges into two separate routes:

• Constitutive Secretory Pathway: Vesicles bud continuously and fuse with the plasma membrane without requiring external stimuli. Peptides processed through this route undergo minimal convertase cleavage and are secreted as rapidly as they are synthesized.
• Regulated Secretory Pathway: Propeptides are actively sorted and packaged into specialized dense-core secretory granules. These granules accumulate in the cytoplasm until an external physiological trigger, such as membrane depolarization or receptor activation, stimulates exocytosis.

Dense-core secretory granules provide the ideal environment for extensive peptide maturation. Inside these maturing granules, proton pumps lower the luminal pH further, reaching values between 5.0 and 5.5. Concurrently, free calcium ion concentrations rise significantly. This acidic, calcium-rich environment is essential because prohormone convertases require low pH and divalent cations to achieve full catalytic activity.

By restricting convertase activity to late-stage granules, the cell prevents premature proteolysis in the endoplasmic reticulum or Golgi. The temporal and spatial regulation of these cellular mechanisms and pathways prevents unregulated enzymatic digestion of immature precursors. The propeptide and its processing enzymes remain safely sequestered together until the microenvironment signals that maturation should proceed.

Dissect Endoproteolytic Cleavage by Prohormone Convertases

The principal molecular scissors responsible for prohormone processing belong to the subtilisin-like proprotein convertase family. Within neuroendocrine tissues, two calcium-dependent serine endoproteases perform the vast majority of internal cleavages: proprotein convertase 1/3 (PC1/3) and proprotein convertase 2 (PC2). Both enzymes recognize specific configurations of basic amino acids, but they exhibit distinct biochemical preferences and operational dynamics.

PC1/3 generally initiates prohormone processing within the trans-Golgi network and early immature secretory granules. It operates effectively at a slightly higher pH than PC2 and often makes the first primary cuts within a large propeptide. PC2 typically activates downstream within mature, highly acidified secretory granules. PC2 activation requires interaction with the neuroendocrine chaperone 7B2, which prevents premature PC2 aggregation and facilitates its autoactivation. Together, these two convertases dismantle complex propeptides into discrete molecular domains.

While textbooks often summarize convertase targets as simple dibasic motifs, enzymatic recognition is far more complex:

• Paired Basic Residues: Sequences such as Lys-Arg and Arg-Arg represent canonical cleavage sites. However, cleavage does not occur at every dibasic pair in a protein. The local secondary structure must present the motif on an exposed, accessible loop.
• Flanking Amino Acid Context: Residues at the P1, P2, P4, and P6 positions strongly influence catalytic efficiency. An arginine at the P1 position is almost universally required. Additional basic residues at P4 or P6 substantially enhance PC1/3 binding affinity.
• Monobasic Cleavage Sites: Select precursors undergo cleavage at isolated arginine residues. These sites typically feature specific flanking residues, such as an arginine or proline located several positions upstream, which compensate for the absence of an adjacent basic partner.
• Structural Inhibition: Post-translational modifications nearby, such as serine phosphorylation or O-linked glycosylation, can sterically block convertases from accessing an otherwise ideal cleavage sequence.

Relying solely on motif prediction algorithms creates an illusion of certainty. Precursor modeling software can flag every potential dibasic pair across an open reading frame. Yet, in living cells, convertase cleavage is strictly regulated by substrate conformation, enzyme abundance, and granule residency time. Endoproteolytic processing is a selective, controlled event rather than an indiscriminate digestion of basic residues.

Track Exopeptidase Trimming and Boundary Resolution

Endoproteolytic cleavage by PC1/3 or PC2 does not produce a mature peptide terminus. Convertases cleave on the carboxyl-terminal side of their target basic residues. Consequently, the newly liberated upstream peptide fragment retains those basic amino acids attached to its C-terminus. An intermediate ending in a Lys-Arg or Arg-Arg extension is biologically incomplete. If left untrimmed, these positively charged terminal residues typically disrupt receptor binding and leave the peptide vulnerable to non-specific degradation.

To resolve this issue, cells employ specialized exopeptidases that trim the intermediate down to its authentic sequence. The primary enzyme responsible for this step in neuroendocrine tissues is carboxypeptidase E (CPE), also known as enkephalin convertase. Carboxypeptidase E is a zinc-dependent exopeptidase localized within secretory granules. It specifically removes basic amino acids (arginine and lysine) one by one from the C-termini of peptide intermediates.

The enzymatic collaboration proceeds in an obligatory two-stage sequence:

• Peptide Sequence
• Downstream Sequence
• (PC1/3 or PC2 Cleavage)
• (Carboxypeptidase E Trimming)

If CPE activity is absent or pathologically reduced, tissues accumulate intermediate peptide fragments retaining C-terminal dibasic extensions. In certain non-neuroendocrine tissues or specific intracellular compartments, a related enzyme termed carboxypeptidase D (CPD) provides redundant or complementary trimming capacity. CPD contains multiple catalytic domains and functions across a broader pH spectrum, including the trans-Golgi network.

Exopeptidase trimming explains why genomic predictions often misidentify peptide boundaries. An investigator inspecting a gene sequence might locate the convertase cleavage motif and assume the peptide ends at that boundary. In reality, the mature product terminates one or two residues upstream, precisely where carboxypeptidase trimming ceases. Without accounting for carboxypeptidase activity, synthetic peptides synthesized for laboratory research will contain extraneous basic residues that distort biological findings.

Catalog Essential Post-Translational Modifications and Chemical Maturation

Cleavage and trimming establish the peptide backbone, but post-translational modifications (PTMs) frequently determine whether that backbone can activate its receptor. Unmodified peptides can be unstable in solution and susceptible to rapid degradation by circulating exopeptidases. Chemical modifications at the termini or along amino acid side chains alter receptor affinity, adjust electrostatic charge, and extend biological half-life.

C-terminal amidation represents one of the most critical modifications in peptide biology. Over half of all known neuropeptides and endocrine hormones require an amidated C-terminus for full biological activity. This modification neutralizes the negative charge of the terminal carboxylate group, creating a neutral amide that frequently fits into hydrophobic receptor binding pockets. Furthermore, amidation protects the peptide from degradation by circulating carboxypeptidases.

Amidation is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM), a bifunctional enzyme residing in secretory granules. PAM executes this transformation through a sequential, two-step biochemical reaction:

• Peptidylglycine Alpha-Hydroxylating Monoxygenase (PHM) Domain: This copper-, ascorbate-, and oxygen-dependent catalytic domain hydroxylates the alpha-carbon of the terminal glycine residue. This yields a peptidyl-alpha-hydroxyglycine intermediate.
• Peptidyl-Alpha-Hydroxyglycine Alpha-Amidating Lyase (PAL) Domain: This zinc-dependent domain cleaves the carbon-nitrogen bond of the hydroxylated intermediate. It releases the mature peptide containing a C-terminal amide group alongside a molecule of glyoxylate.

Other post-translational modifications contribute equally profound functional transformations:

• N-Terminal Pyroglutamate Formation: When an N-terminal cleavage reveals a glutamine residue, the enzyme glutaminyl cyclase catalyzes an intramolecular cyclization. This reaction converts the glutamine into pyroglutamate, removing the positive charge of the free amine and protecting the N-terminus against aminopeptidases.
• Serine Acylation: Ghrelin represents a striking example where side-chain acylation dictates function. The enzyme ghrelin O-acyltransferase attaches an eight-carbon fatty acid (octanoate) to a specific serine residue. Non-acylated ghrelin fails to bind or activate the growth hormone secretagogue receptor.
• N-Terminal Acetylation: Peptide N-terminal acetyltransferases transfer an acetyl group from acetyl-CoA to the N-terminal amino acid. In the case of beta-endorphin, N-terminal acetylation completely eliminates analgesic potency and receptor binding.
• Tyrosine Sulfation: Tyrosylprotein sulfotransferase in the trans-Golgi transfers sulfate groups from PAPS to specific tyrosine residues. This modification is essential for the high-affinity receptor interactions of cholecystokinin.
• Phosphorylation and Glycosylation: Kinases and glycosyltransferases add phosphate groups or complex oligosaccharides to serine, threonine, or asparagine residues. These modifications alter electrostatic surfaces, modulate aggregation, and control clearance rates.

A peptide that possesses the correct amino acid sequence but lacks the appropriate post-translational modification is functionally distinct from the endogenous hormone. When interpreting preclinical peptide research, researchers must verify whether the tested molecule incorporates the exact chemical modifications produced by native processing pathways. Failing to account for PTMs produces data that cannot be replicated in physiological models.

Analyze Classical Processing Models Across Differentiated Tissues

The clearest evidence that precursor sequence does not dictate mature peptide identity comes from tissue-specific processing. Distinct cell types can transcribe the exact same gene, translate the identical prepropeptide, yet secrete entirely different signaling molecules. The identity of the secreted product is dictated by the specific repertoire of prohormone convertases and modifying enzymes expressed in each differentiated cell.

The Proglucagon Paradigm: Differential Convertase Expression

The proglucagon precursor illustrates how enzymatic specialization creates functional divergence from a single gene. The proglucagon gene is expressed in pancreatic alpha cells, intestinal L cells, and select neurons within the brainstem. The translated precursor contains the sequences for glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glicentin, oxyntomodulin, and intervening peptides.

In pancreatic alpha cells, the processing machinery is dominated by prohormone convertase 2 (PC2). This enzymatic profile directs cleavage of the precursor to release mature glucagon, which regulates hepatic glucose output. The remaining C-terminal portion of the precursor is left largely intact as an unprocessed fragment termed the major proglucagon fragment. Alpha cells also generate glicentin-related pancreatic polypeptide (GRPP) from the N-terminus.

In intestinal L cells, the enzymatic landscape is reversed. L cells express prohormone convertase 1/3 (PC1/3) but lack significant PC2 activity. Under PC1/3 direction, proglucagon is cleaved along an entirely different pathway:

• Glucagon Domain Preservation: The glucagon sequence remains embedded within larger precursors known as glicentin and oxyntomodulin, rather than being released as free glucagon.
• Incretin Hormone Liberation: PC1/3 cleaves the C-terminal cassette to liberate GLP-1 and GLP-2. GLP-1 undergoes subsequent trimming and amidation to produce active incretin peptides that enhance glucose-dependent insulin secretion.

The identical precursor thus yields a hyperglycemic hormone in the pancreas and metabolic incretin hormones in the gut. Nothing in the proglucagon sequence specifies this division; the cellular expression of PC1/3 versus PC2 determines the biological outcome.

Proopiomelanocortin (POMC): Layered and Sequential Processing

Proopiomelanocortin (POMC) demonstrates that processing can proceed through sequential tiers across anatomical regions. The POMC propeptide serves as a complex polyvalent precursor containing adrenocorticotropic hormone (ACTH), multiple melanocyte-stimulating hormones (alpha, beta, and gamma-MSH), and beta-endorphin.

In the corticotrope cells of the anterior pituitary gland, PC1/3 is the primary active convertase. This limited processing environment cleaves POMC into an intact 39-amino-acid ACTH peptide and beta-lipotropin. The corticotrope cell secretes ACTH into systemic circulation to stimulate adrenal glucocorticoid production.

In the melanotrope cells of the intermediate pituitary lobe and hypothalamic neurons, both PC1/3 and PC2 are abundantly expressed. In these cells, processing continues downstream through secondary cleavages:

• Secondary ACTH Cleavage: PC2 cleaves intact ACTH into two smaller fragments: corticotropin-like intermediate peptide (CLIP) and an unamidated ACTH(1-13) intermediate.
• Terminal Maturation: Carboxypeptidase E trims basic residues from the ACTH(1-13) intermediate, PAM amidates its C-terminus, and an acetyltransferase acetylates the N-terminus. This multi-step cascade converts the non-melanotropic precursor into mature alpha-MSH.
• Endorphin Maturation: Concurrently, beta-lipotropin is cleaved to yield beta-endorphin, which may undergo subsequent N-terminal acetylation to regulate its opioid receptor activity.

The intermediate pituitary does not simply release a mixture of fragments. It uses coordinated, multi-enzyme processing to convert a systemic endocrine signal (ACTH) into localized neurochemical regulators (alpha-MSH and beta-endorphin).

Proinsulin: Ordered Cleavage Across Species Contexts

Proinsulin processing provides a classic example of ordered, stepwise proteolysis within a single cell type. Synthesized as preproinsulin in pancreatic beta cells, signal peptide cleavage yields proinsulin. Proinsulin consists of an N-terminal B chain, an intervening connecting peptide (C-peptide), and a C-terminal A chain. Three disulfide bonds form in the endoplasmic reticulum, orienting the A and B chains in close spatial proximity.

Maturation requires the excision of C-peptide to yield mature, active two-chain insulin. This process is initiated within the regulated secretory pathway through sequential cleavages at two distinct dibasic junctions: the B-chain/C-peptide junction and the C-peptide/A-chain junction.

In human pancreatic beta cells, PC1/3 initiates cleavage predominantly at the B-chain/C-peptide boundary. PC2 contributes significantly to the subsequent cleavage at the C-peptide/A-chain junction. Following endoprotease action, carboxypeptidase E removes the remaining basic residues from the newly liberated B chain and C-peptide termini. Research demonstrates that rodent beta cells display slightly different convertase redundancies, emphasizing that processing dynamics can vary across species.

Evaluate Analytical Methods and Avoid Common Identification Errors

Because precursor processing involves many sequential steps, determining what a cell actually secretes requires precise analytical tools. Researchers cannot rely on theoretical predictions or indirect assays to confirm peptide identity. Misinterpreting analytical data leads to serious errors regarding peptide function, stability, and concentration.

Limitations of Immunoassays and Histology

Immunoassays such as ELISA, radioimmunoassays (RIA), and immunohistochemistry (IHC) are widely used to measure peptides. However, these methods rely on antibody binding affinity, which presents significant limitations in precursor research:

• Epitope Cross-Reactivity: An antibody raised against a 14-amino-acid mature peptide typically recognizes an epitope of only four to six residues. That antibody will bind with high affinity to the mature peptide, its partially trimmed intermediates, and the intact prohormone.
• Inability to Detect PTMs: Standard antibodies rarely distinguish between amidated and non-amidated C-termini, or between non-acylated and acylated peptide forms. An ELISA may report robust peptide levels when the sample contains exclusively inactive, unamidated precursors.
• Spatial Ambiguity: Immunohistochemistry can establish that a propeptide is present within a tissue or cell type. It cannot prove that the propeptide undergoes successful cleavage, trimming, or secretion as an active ligand.

The Role of Mass Spectrometry in Neuropeptidomics

Tandem mass spectrometry (MS/MS) represents the gold standard for characterizing endogenous peptide processing. Unlike antibody-based assays, mass spectrometry measures the exact mass-to-charge ratio of intact molecules and fragments them to determine primary sequence.

Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) can resolve the exact N-terminal and C-terminal boundaries of a peptide without requiring prior knowledge of cleavage sites. Fragmentation spectra establish whether basic residues were successfully trimmed by carboxypeptidase E. Furthermore, precise mass shifts identify specific post-translational modifications, such as the addition of 42 Da for an acetyl group, 80 Da for a sulfate group, or 126 Da for an octanoyl group.

Even mass spectrometry faces practical limitations:

• Extraction Artifacts: Post-mortem tissue collection or delayed cell lysis activates non-specific lysosomal and cytosolic proteases. These degrading enzymes cleave precursors randomly, generating artificial peptide fragments that do not represent endogenous processing. Rapid heat denaturation or immediate acid extraction is necessary to preserve physiological profiles.
• Mass Equivalence: Measuring a single intact mass (MS1) is never sufficient to establish peptide identity. Multiple peptide combinations and isobaric amino acid substitutions can produce identical molecular weights. Definitive identification requires MS/MS fragmentation data that match theoretical spectra.
• Low Abundance and Ionization Suppression: Highly modified or hydrophobic peptides may ionize poorly in electrospray sources, making them difficult to detect alongside abundant structural proteins.

Edman Degradation and Historic Sequencing

Edman degradation historically served as the primary method for resolving peptide sequences by sequentially cleaving and identifying N-terminal residues. While highly accurate for unmodified peptides, the Edman chemical reaction requires a free, unblocked N-terminal alpha-amino group.

Consequently, Edman sequencing fails entirely when applied to peptides bearing N-terminal modifications such as pyroglutamate or acetylation. Because a vast proportion of endogenous bioactive peptides possess blocked N-termini to resist aminopeptidase attack, historical studies using Edman degradation often failed to detect or correctly sequence these critical signaling molecules.

Apply Rigorous Standards to Peptide Identity Verification

Laboratory professionals and researchers working with peptide materials must evaluate physical testing records carefully. High-performance liquid chromatography (HPLC) and mass spectrometry data provided on a Certificate of Analysis (COA) confirm chemical properties for an isolated synthesized sample. However, these documents must be interpreted within their actual analytical scope.

When reviewing laboratory certificates of analysis, researchers must distinguish between relative purity and molecular identity. An analytical HPLC trace demonstrating 98% purity indicates that a single predominant peak absorbs ultraviolet light at a specified wavelength (typically 214 nm or 220 nm). It does not, by itself, verify that the synthesized peptide matches the physiological, endogenous signaling molecule.

Researchers should systematically evaluate several analytical parameters:

• Accurate Mass vs. Predicted Mass: High-resolution mass spectrometry should yield a molecular weight that matches the theoretical monoisotopic mass to within parts-per-million accuracy. This calculation must account for the loss of mass from terminal amidation (loss of 0.98 Da relative to a free carboxylate) or the addition of specific PTMs.
• Counter-Ion Content: Solid-phase peptide synthesis typically utilizes trifluoroacetic acid (TFA) for cleavage and purification. Unless explicitly converted to an acetate or hydrochloride salt, the peptide material will contain significant quantities of residual TFA counter-ions. These counter-ions contribute to total gross mass without contributing to peptide content.
• Peptide Content vs. Gross Weight: Gross powder weight includes the peptide, bound counter-ions, and residual moisture. A vial containing 10 mg of lyophilized powder with 98% chromatographic purity may only contain 7.5 mg of actual peptide molecule. Quantitative amino acid analysis or nitrogen determination is required to establish net peptide content.
• Batch-Specific Scope: An analytical report reflects only the specific sample or batch submitted to the instrument. It cannot establish the integrity of other lots, nor can it prevent degradation resulting from improper reconstitution, temperature fluctuations, or microbial contamination.

By understanding how analytical testing methods operate, researchers avoid overinterpreting laboratory records. A COA confirms that a synthetic process yielded a specific chemical structure. It remains the researcher's responsibility to confirm whether that synthetic sequence reflects the mature, bioactive signaling product generated by native biological processing.

Key Takeaways

• Genomic Sequence Is a Blueprint: A peptide gene encodes a larger precursor containing signal sequences, spacer elements, and cleavage motifs; it does not directly represent the final secreted ligand.
• Processing Is Multi-Stage: Mature peptide generation requires initial endoproteolytic cleavage by convertases (such as PC1/3 and PC2) followed by mandatory exopeptidase trimming (via carboxypeptidase E) to remove terminal basic residues.
• Cellular Machinery Dictates Identity: The identical precursor generates completely different bioactive peptide sets depending on the specific enzymes expressed in the synthesizing tissue, as demonstrated by proglucagon in the pancreas versus the intestine.
• Post-Translational Remodeling Is Critical: Terminal modifications like C-terminal amidation and N-terminal pyroglutamate formation are essential for biological activity and enzymatic stability, not optional decorations.
• Analytical Verification Requires Precision: Theoretical sequence prediction algorithms and cross-reactive antibody immunoassays cannot prove peptide identity; definitive verification requires high-resolution tandem mass spectrometry with fragmentation data.

Endogenous peptide signaling depends on the precise, compartmentalized execution of proteolysis and chemical remodeling within the secretory pathway.

Sources

1. Neuropeptidomics Mass Spectrometry Reveals Signaling Networks Generated By Distinct Protease Pathways in Human Systems: Commentary Review
2. The making of insulin in health and disease - PMC
3. Severe block in processing of proinsulin to insulin ...
4. Understanding peptide hormones: from precursor proteins to bioactive molecules
5. Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics
6. Developing Mass Spectrometry for the Quantitative Analysis of Neuropeptides
7. Proc. Natl. Acad. Sci. USA